Fundz

Ocelot Bio, Inc. reported raising $36 Million in an initial SEC Form D filing, from an offering of $38 Million

PRIVATEApr 15, 2021$36M of $38M raised

Amount Raised

$36 Million

$36 Million sold, per SEC Form D (first sale Apr 15, 2021)

Round Type

Venture

San DiegoBiotechnologyHealthcareHealth Care

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Ocelot Bio that raised within 45 days of this round, from Fundz verified event records.

  • Climb Bio, Inc. raised $60M on May 28, 2021.
  • Axial Therapeutics raised $4.8M (Seed) on May 26, 2021.
  • Harrow raised $11M on May 14, 2021.
  • Nuvalent raised $135M on May 12, 2021.
  • Tellus Therapeutics raised an undisclosed amount (Seed) on May 12, 2021.
  • Nuvalent raised $135M (Series B) on May 11, 2021.

Who to call at Ocelot Bio, and when

A new round usually means Ocelot Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Ocelot Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ocelot Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ocelot Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ocelot Bio

Location

San Diego, California, United States

About

Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively address portal hypertension induced complications of end-stage liver disease (ESLD). These complications include hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, both of which may lead to serious and life-threatening outcomes. Ocelot Bio has initiated a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 Orphan Drug Designation in the treatment of hepatorenal syndrome. The company was founded by leading experts in therapeutic peptide development and is backed by a strong syndicate of investors including Venrock, RA Capital Management and Vivo Capital. For more information, visit www.ocelotbio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ocelot Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts3 people are listed at Ocelot Bio. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Ocelot Bio's next move

See what Strategic adds

Ocelot Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.